Search

Your search keyword '"Owen, Dwight H."' showing total 340 results

Search Constraints

Start Over You searched for: Author "Owen, Dwight H." Remove constraint Author: "Owen, Dwight H."
340 results on '"Owen, Dwight H."'

Search Results

1. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

2. Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients

3. Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study

4. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

5. Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy

9. Acute kidney injury in patients treated with immune checkpoint inhibitors

10. Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia

12. Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 TrialIntracranial Efficacy of Selpercatinib in RET Fusion+ NSCLC

13. Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

14. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

15. Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy

17. Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis.

25. Therapy for Stage IV Non–Small Cell Lung Cancer With and Without Driver Alterations: ASCO Living Guideline Clinical Insights.

27. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3

28. Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study

34. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

36. Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer

42. Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

43. Data from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

44. Metabolic Dysregulation Explains the Diverse Impacts of Obesity in Males and Females with Gastrointestinal Cancers

46. Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

47. Immune-related adverse event in the emergency department: methodology of the immune-related emergency disposition index (IrEDi).

49. Detection of novel therapies using a multi‐national , multi‐institutional registry of cutaneous immune‐related adverse events and management

50. Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression

Catalog

Books, media, physical & digital resources